After taking expert advice from world class toxicology and DMPK experts, OncoTherics has commenced an innovative DMPK equivalence programme. The close chemical relationship between OCT1002 and OCT1004 together with OCT1004’s excellent safety record in Phase I clinical trials, has allowed the design of a series of studies to demonstrate comparative safety profiles for both assets.

The company has applied for SMART grant funding in Poland and the company’s founders have provided follow-on investment to support the start of the first metabolism studies.